Wave Life Sciences (WVE) stock slides 6% — what traders are watching next
Wave Life Sciences shares fell 6.2% to $15.95 Friday, underperforming the flat Nasdaq Biotechnology Index. The company expects more Phase 1 obesity trial data in Q1 2026. A December SEC filing said Wave’s equity raise, including over-allotments, was expected to bring in about $402.5 million. Early data showed WVE-007 reduced visceral fat by 9.4% at three months in a 32-person cohort.